Accelerating Deformulation: A New Whitepaper from Malvern Instruments for Generic Tablet Development
A new whitepaper from Malvern Instruments on Oral Solid Dose (OSD) deformulation demonstrates how the analytical technique of Morphologically Directed Raman Spectroscopy (MDRS) can be used to accelerate the development of generic products to a successful conclusion.
Deformulation, the unpicking and investigation of a reference labeled drug (RLD), enables generic developers to understand the features of a product that define its clinical performance. “Accelerating the deformulation workflow for oral solid dosage forms” reviews the current regulatory landscape associated with generic development and considers the workflow for preparing OSD product Abbreviated New Drug Applications (ANDAs). Case studies demonstrate the breadth and value of the information generated by MDRS within this context.
MDRS enables component specific data to be obtained for multi-component samples and is made possible by the capabilities of systems such as the Morphologi G3-ID from Malvern Instruments. This instrument combines automated analytical imaging, which can be used to gather statistically relevant size and shape data, with Raman spectroscopy, which enables component identification. The case studies in the whitepaper show how MDRS can be applied to efficiently identify and quantify the components in an RLD; determine the polymorphic form of the active pharmaceutical ingredient; and to gain insight into the manufacturing methods employed. Such information supports successful deformulation and the development of generics with well-understood performance and robust bioequivalence.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.